Disclosures for "Top Line Results of the Phase 1b, Open-label, Multiple Ascending Dose Proof of Concept Study of the PIKfyve Inhibitor VRG50635 in Familial and Sporadic Amyotrophic Lateral Sclerosis "
-
Dr. Cadavid has received personal compensation for serving as an employee of Verge Genomics. Dr. Cadavid has received personal compensation for serving as an employee of X4 Pharmaceuticals. Dr. Cadavid has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pheno Therapeutics. Dr. Cadavid has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novo Nordisk. Dr. Cadavid has stock in Verge Genomics.
-
Dr. Scannevin has received personal compensation for serving as an employee of Verge Genomics. Dr. Scannevin has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Hoffmann has received personal compensation for serving as an employee of Xencor. Dr. Hoffmann has received personal compensation for serving as an employee of Verge Genomics. Dr. Hoffmann has stock in Xencor.
-
Dr. Tarachandani has received personal compensation for serving as an employee of Verge Genomics. Dr. Tarachandani has stock in Verge Genomics.
-
Dr. Choi has received personal compensation for serving as an employee of Verge Genomics. Dr. Choi has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Modality AI. Dr. Choi has stock in Nektar Therapeutics. Dr. Choi has stock in Verge Genomics. Dr. Choi has stock in Modality AI.
-
Dr. Swami has nothing to disclose.
-
Joanna Haas has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Vergegenomics . Joanna Haas has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Nimbus Therapeutics . Joanna Haas has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for X4 Pharmaceuticals.
-
Dr. Schmidt has received personal compensation for serving as an employee of Kypha Inc.. Dr. Schmidt has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Verge Genomics. Dr. Schmidt has stock in Kypha Inc. Dr. Schmidt has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Shook has nothing to disclose.
-
Author has nothing to disclose
-
Author has nothing to disclose
-
The institution of Dr. Van Damme has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for QurAlis. The institution of Dr. Van Damme has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. The institution of Dr. Van Damme has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for VectorY. The institution of Dr. Van Damme has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NRG Therapeutics. The institution of Dr. Van Damme has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Van Damme has received research support from CSL Behring.
-
Dr. Tienari has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck GmBH. Dr. Tienari has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Tienari has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jansen. The institution of Dr. Tienari has received research support from Helsinki University Hospital. The institution of Dr. Tienari has received research support from Sigrid Juselius Foundation. The institution of Dr. Tienari has received research support from Maze Therapeutics. The institution of Dr. Tienari has received research support from Verge genomics. The institution of Dr. Tienari has received research support from University of Helsinki. The institution of Dr. Tienari has received research support from Private donor. Dr. Tienari has received intellectual property interests from a discovery or technology relating to health care.
-
Prof. Solje has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Prof. Solje has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Prof. Solje has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EISAI. Prof. Solje has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Prof. Solje has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Lundbeck. Prof. Solje has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche.
-
Manu Jokela has nothing to disclose.
-
Dr. Genge has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AL-S Pharma. Dr. Genge has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amylyx. Dr. Genge has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Quralis. Dr. Genge has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MTPA. Dr. Genge has received personal compensation in the range of $0-$499 for serving as a Consultant for WAVE. Dr. Genge has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for eikonizo. Dr. Genge has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for rapa.
-
Colleen O'Connell has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MT Pharma. Colleen O'Connell has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Colleen O'Connell has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Colleen O'Connell has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for MT PHarma. The institution of Colleen O'Connell has received research support from Biogen. The institution of Colleen O'Connell has received research support from Calico. The institution of Colleen O'Connell has received research support from Praxis Spinal Cord Institute. The institution of Colleen O'Connell has received research support from Verge. Colleen O'Connell has a non-compensated relationship as a Steering Committee with World Rehabilitation Alliance that is relevant to AAN interests or activities.
-
Dr. van Eijk has nothing to disclose.
-
The institution of Dr. Van den Berg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amylyx. The institution of Dr. Van den Berg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ferrrer. The institution of Dr. Van den Berg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. The institution of Dr. Van den Berg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. The institution of Dr. Van den Berg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. The institution of Dr. Van den Berg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Van den Berg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. The institution of Dr. Van den Berg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ArgenX. The institution of Dr. Van den Berg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Projenx. Dr. Van den Berg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Corcept. The institution of Dr. Van den Berg has received research support from Netherlands ALS Foundation.